v3.25.1
Condensed Consolidated Statements of Equity (Unaudited) - USD ($)
shares in Millions, $ in Millions
Total
Common stock
Treasury Stock, Common
Additional paid-in capital
Retained earnings
Accumulated other comprehensive loss
Noncontrolling interest
Beginning balance at Dec. 31, 2023 $ 10,397 $ 18 $ (6,533) $ 20,180 $ (1,000) $ (2,305) $ 37
Beginning balance (in shares) at Dec. 31, 2023   1,766          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 1,369 $ 0 0 0 1,369 0 0
Other comprehensive income (loss), net of tax (149) 0 0 0 0 (149) 0
Dividends declared (2,753) 0 0 0 (2,753) 0 0
Purchases of treasury stock (1,324) $ 0 (1,324) 0 0 0 0
Purchases of treasury stock (in shares)   (7)          
Stock-based compensation plans and other 504 $ 0 28 476 0 0 0
Stock-based compensation plans and other (in shares)   7          
Change in noncontrolling interest 3 $ 0 0 0 0 0 3
Ending balance at Mar. 31, 2024 8,047 $ 18 (7,829) 20,656 (2,384) (2,454) 40
Ending balance (in shares) at Mar. 31, 2024   1,766          
Beginning balance at Dec. 31, 2024 3,364 $ 18 (8,201) 21,333 (7,900) (1,925) 39
Beginning balance (in shares) at Dec. 31, 2024   1,765          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 1,286 $ 0 0 0 1,286 0 0
Other comprehensive income (loss), net of tax 183 0 0 0 0 183 0
Dividends declared (2,913) 0 0 0 (2,913) 0 0
Purchases of treasury stock (963) $ 0 (963) 0 0 0 0
Purchases of treasury stock (in shares)   (5)          
Stock-based compensation plans and other 502 $ 0 27 475 0 0 0
Stock-based compensation plans and other (in shares)   6          
Change in noncontrolling interest 3 $ 0 0 0 0 0 3
Ending balance at Mar. 31, 2025 $ 1,462 $ 18 $ (9,137) $ 21,808 $ (9,527) $ (1,742) $ 42
Ending balance (in shares) at Mar. 31, 2025   1,766